Skip to main content

Table 3 ERβ1 expression levels in a population of breast cancer patients diagnosed at Mayo Clinic Rochester (cohort 1) and its association with other biomarkers, tumor grade and nodal status

From: ERβ1: characterization, prognosis, and evaluation of treatment strategies in ERα-positive and -negative breast cancer

Disease characteristics   ERβ1 status Nucleus Cytoplasm
    # of Pts. (%) # of Pts. (%)
ERα Positive (n = 170) Negative/Low 114 (67.1) 151 (88.8)
Moderate 52 (30.6) 19 (11.2)
High 4 (2.4) 0 (0)
Negative (n = 14) Negative/Low 7 (50.0) 13 (92.9)
Moderate 7 (50.0) 1 (7.1)
High 0 (0) 0 (0)
HER2 Positive (n = 27) Negative/Low 20 (74.1) 24 (88.9)
Moderate 7 (25.9) 3 (11.1)
High 0 (0) 0 (0)
Negative (n = 145) Negative/Low 94 (64.8) 131 (90.4)
Moderate 47 (32.4) 14 (9.7)
High 4 (2.8) 0
Ki67 ≤ 10% (61) Negative/Low 39 (63.9) 57 (93.4)
Moderate 21 (34.4) 4 (6.6)
High 1 (1.6) 0 (0)
> 10% (120) Negative/Low 79 (65.8) 104 (86.7)
Moderate 38 (31.7) 16 (13.3)
High 3 (2.5) 0 (0)
Tumor grade Grade 1–2 (136) Negative/Low 89 (65.4) 122 (89.7)
Moderate 44 (32.4) 14 (10.3)
High 3 (2.2) 0
Grade 3 (45) Negative/Low 31 (68.9) 41 (91.1)
Moderate 13 (28.9) 4 (8.9)
High 1 (2.2) 0 (0)
Nodal disease Present (72) Negative/Low 44 (61.1) 65 (90.3)
Moderate 24 (33.3) 7 (9.7)
High 4 (5.6) 0 (0)
Not present (112) Negative/Low 77 (68.8) 99 (88.4)
Moderate 35 (31.3) 13 (11.6)
   High 0 (0) 0 (0)
\